S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Laser breakthrough could send stock soaring 2,467% (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Laser breakthrough could send stock soaring 2,467% (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Laser breakthrough could send stock soaring 2,467% (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Laser breakthrough could send stock soaring 2,467% (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
NASDAQ:REGN

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price & News

$806.95
+13.94 (+1.76%)
(As of 08/11/2023 08:48 PM ET)
Compare
Today's Range
$794.69
▼
$809.66
50-Day Range
$692.45
▼
$806.95
52-Week Range
$572.22
▼
$837.55
Volume
526,100 shs
Average Volume
616,693 shs
Market Capitalization
$88.53 billion
P/E Ratio
21.33
Dividend Yield
N/A
Price Target
$873.48
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
8.2% Upside
$873.48 Price Target
Short Interest
Healthy
1.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.97
Upright™ Environmental Score
News Sentiment
0.65mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$1.25 M Sold Last Quarter
Proj. Earnings Growth
2.45%
From $35.16 to $36.02 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

291st out of 987 stocks

Pharmaceutical Preparations Industry

120th out of 463 stocks

See Top Rated MarketRank™ Stocks Here

REGN stock logo

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Price History

REGN Stock News Headlines

August 13, 2023 | finance.yahoo.com
4 big deal reports: Michael Kors parent rockets on huge buyout deal with Tapestry
August 13, 2023 | americanbankingnews.com
Bonnie L. Bassler Sells 853 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock
August 14, 2023 | Behind the Markets (Ad)
Don't miss your 3rd and final chance!
You missed your chance on Pfizer... ...which soared 600% after it released Lipitor in 1997. You missed your chance on Bristol Myers... ...which soared 500% after releasing Metformin in 1994. Both of these drugs broke records and made their investors rich. But there's one opportunity you didn't miss - and Morgan Stanley predicts it will be bigger than both of these combined! Get all the details here.
August 12, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of "Moderate Buy" by Brokerages
August 10, 2023 | msn.com
Regeneron's Aflibercept 8mg Shows Sustained Vision Gains At Two Years
August 10, 2023 | finance.yahoo.com
Regeneron (REGN) to Buy Decibel, Gains on Hearing Loss Therapies
August 10, 2023 | finance.yahoo.com
Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration
August 10, 2023 | finance.yahoo.com
Bayer: eye drug shows vision gains in 70% of patients at higher dose
August 14, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
August 9, 2023 | finance.yahoo.com
Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals
August 8, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $912.00 Price Target at Morgan Stanley
August 8, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded by StockNews.com to "Strong-Buy"
August 7, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $900.00
August 6, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $820.00 at Royal Bank of Canada
August 4, 2023 | msn.com
Regeneron Shares Jump After Saying It Expects an FDA Decision on Its Eye Treatment Soon
August 4, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Arthur F. Ryan Sells 100 Shares of Stock
August 4, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Increased to $950.00 by Analysts at Oppenheimer
August 4, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Earnings Results
August 3, 2023 | msn.com
Why Is Regeneron Pharmaceuticals Moving Higher Today?
August 3, 2023 | markets.businessinsider.com
Regeneron Pharmaceuticals Q2 Profit Increases, beats estimates
August 3, 2023 | finance.yahoo.com
Is Regeneron Pharmaceuticals (REGN) Modestly Overvalued?
August 3, 2023 | msn.com
Regeneron Surmounts Its 200-Day Line On A Handy Second-Quarter Beat
August 3, 2023 | msn.com
Regeneron Pharma beats quarterly profit estimates
August 3, 2023 | finance.yahoo.com
Regeneron Reports Second Quarter 2023 Financial and Operating Results
August 2, 2023 | benzinga.com
Regeneron Pharmaceuticals Earnings Preview
August 2, 2023 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Zimmer Biomet Holdings (ZBH), Regeneron (REGN) and Addus Homecare (ADUS)
August 1, 2023 | finance.yahoo.com
Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings
8/03/2023
Today
8/14/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
CIK
872589
Web
www.regeneron.com
Phone
(914) 847-7000
Fax
914-347-2113
Employees
11,851
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$873.48
High Stock Price Forecast
$1,045.00
Low Stock Price Forecast
$650.00
Forecasted Upside/Downside
+8.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
22 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$37.83
Trailing P/E Ratio
21.33
Forward P/E Ratio
22.95
P/E Growth
2.42
Net Income
$4.34 billion
Net Margins
33.93%
Pretax Margin
37.69%
Return on Equity
19.19%
Return on Assets
14.94%

Debt

Debt-to-Equity Ratio
0.11
Current Ratio
5.45
Quick Ratio
4.64

Sales & Book Value

Annual Sales
$12.17 billion
Price / Sales
7.27
Cash Flow
$44.53 per share
Price / Cash Flow
18.12
Book Value
$218.92 per share
Price / Book
3.69

Miscellaneous

Outstanding Shares
109,710,000
Free Float
100,023,000
Market Cap
$88.53 billion
Optionable
Optionable
Beta
0.21

Social Links

(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Leonard S. Schleifer M.D.Dr. Leonard S. Schleifer M.D. (Age 70)
    Ph.D., Co-Founder, Pres, CEO & Co-Chairman
    Comp: $7M
  • Dr. George D. Yancopoulos M.D. (Age 63)
    Ph.D., Co-Founder, Pres, Chief Scientific Officer & Co-Chairman
    Comp: $6.59M
  • Mr. Robert E. Landry Jr.Mr. Robert E. Landry Jr. (Age 59)
    Exec. VP of Fin. & CFO
    Comp: $1.84M
  • Dr. Andrew J. Murphy Ph.D. (Age 64)
    Exec. VP of Research
    Comp: $1.62M
  • Mr. Daniel P. Van Plew (Age 50)
    Exec. VP and GM of Industrial Operations & Product Supply
    Comp: $1.95M
  • Ms. Marion E. McCourtMs. Marion E. McCourt (Age 63)
    Exec. VP of Commercial
    Comp: $1.5M
  • Ms. Patrice Gilooly
    Sr. VP of Quality Assurance & Operations
  • Mr. Christopher R. FenimoreMr. Christopher R. Fenimore (Age 52)
    Sr. VP, Head of Accounting & Controller
  • Mr. Gerald Underwood
    Sr. VP of Technical Operations
  • Mr. Bob McCowan
    Sr. VP of IT & Chief Information Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price forecast for 2023?

22 equities research analysts have issued twelve-month price objectives for Regeneron Pharmaceuticals' stock. Their REGN share price forecasts range from $650.00 to $1,045.00. On average, they anticipate the company's stock price to reach $873.48 in the next year. This suggests a possible upside of 8.2% from the stock's current price.
View analysts price targets for REGN or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2023?

Regeneron Pharmaceuticals' stock was trading at $721.49 on January 1st, 2023. Since then, REGN stock has increased by 11.8% and is now trading at $806.95.
View the best growth stocks for 2023 here.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our REGN earnings forecast.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported $10.24 EPS for the quarter, beating analysts' consensus estimates of $8.48 by $1.76. The biopharmaceutical company earned $3.16 billion during the quarter, compared to the consensus estimate of $3.02 billion. Regeneron Pharmaceuticals had a net margin of 33.93% and a trailing twelve-month return on equity of 19.19%. Regeneron Pharmaceuticals's revenue was up 10.5% compared to the same quarter last year. During the same period last year, the business posted $9.77 EPS.
Read the conference call transcript.

What ETFs hold Regeneron Pharmaceuticals' stock?

ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Dynamic Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA), Subversive Mental Health ETF (SANE) and 2ndVote Life Neutral Plus ETF (LYFE).

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Bank Julius Baer & Co. Ltd Zurich (67.91%), BlackRock Inc. (8.28%), Capital World Investors (5.06%), Capital International Investors (2.69%), Geode Capital Management LLC (2.08%) and Northern Trust Corp (0.94%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $806.95.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $88.53 billion and generates $12.17 billion in revenue each year. The biopharmaceutical company earns $4.34 billion in net income (profit) each year or $37.83 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

The company employs 11,851 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 8/14/2023 by MarketBeat.com Staff

My Account -